Products
Birtamimab Biosimilar Monoclonal Antibody (SAA1) for Research
Cat No.: GMP-Bios-ab-072
Pre-Made Birtamimab biosimilar, Whole mAb, Anti-SAA1 Antibody: Anti-PIG4/SAA/SAA2/TP53I4 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-072-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Birtamimab biosimilar, Whole mAb, Anti-SAA1 Antibody: Anti-PIG4/SAA/SAA2/TP53I4 therapeutic antibody |
| INN Name | Birtamimab |
| Target | SAA1 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2018 |
| Year Recommended | 2019 |
| Companies | Neotope Biosciences;Onclave Therapeutics;Prothena |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Amyloid light-chain amyloidosis |
| Development Tech | na |
About target - SAA1
1. Protein Serum amyloid A-1 protein
2. Gene SAA1
3. Organism Homo sapiens (Human)
Function
Major acute phase protein.
